Lasker George F, Maley Jason H, Kadowitz Philip J
Department of Pharmacology, Tulane University School of Medicine, 1430 Tulane Avenue, SL83, New Orleans, LA 70112-2699, USA.
Adv Pharmacol Sci. 2010;2010. doi: 10.1155/2010/730861.
Erectile dysfunction (ED) affects up to 50% of men between the ages of 40 and 70. Treatment with PDE-5 inhibitors is effective in the majority of men with ED. However, PDE-5 inhibitors are not effective when levels of nitric oxide (NO), the principle mediator of erection, are low. The pharmacologic actions of three new potential treatments for ED are discussed in this paper: (1) sGC stimulators/activators, (2) Rho-kinase inhibitors, and (3) sodium nitrite.
勃起功能障碍(ED)影响着40至70岁之间高达50%的男性。磷酸二酯酶-5(PDE-5)抑制剂治疗对大多数勃起功能障碍男性有效。然而,当勃起的主要介质一氧化氮(NO)水平较低时,PDE-5抑制剂无效。本文讨论了三种新型勃起功能障碍潜在治疗药物的药理作用:(1)可溶性鸟苷酸环化酶(sGC)刺激剂/激活剂,(2)Rho激酶抑制剂,以及(3)亚硝酸钠。